Jonathan D. Marotti, MD
Title(s)
Associate Professor of Pathology and Laboratory Medicine
Department(s)
Pathology and Laboratory Medicine
Education
Dartmouth Medical School, 2005
Anatomic and Clinical Pathology Residency, Beth Israel Deaconess Medical Center, 2005-2009
Breast Pathology Fellowship, Beth Israel Deaconess Medical Center, 2009-2010
Cytopathology Fellowship, Dartmouth-Hitchcock Medical Center, 2010-2011
Programs
Dartmouth Cancer Center
Contact Information
Professional Interests
Breast pathology
Cytopathology
Seven-year retrospective review of medical microbiologist consultations on cytology specimens at an academic medical center. Surgical management and long-term follow-up of a traumatic intrastromal epithelial cyst. Reply to: "Comments on the paper 'Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer' by Y. Chen et al.". Quantitative proteomics analysis of triple-negative breast cancers. Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer. A multi-model approach integrating whole-slide imaging and clinicopathologic features to predict breast cancer recurrence risk. Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation. Does ROSE matter? Evaluation of final diagnostic, PD-L1 immunohistochemistry, and molecular testing yields of CT-guided lung biopsies performed before and after the onset of the COVID-19 pandemic. Chondrolipoma of the Breast: A Myofibroblastoma Variant or a Distinct Lesion? |
|